FDA approves Genentech's Alecensa for advanced lung cancer patients with few options

The Food and Drug Administration has approved an experimental Genetech drug for patients with a certain type of lung cancer who have few other options. Alecensa was approved for patients with advanced non-small cell lung cancer with a mutation in a gene called ALK who have relapsed after treatment with Pfizer Inc.’s Xalkori or who could not tolerate that drug.